As placebo spoils PhIII trial, Acadia does not intend to stage further Nuplazid studies in schizophrenia

Af­ter years of try­ing to ex­pand the mar­ket ter­ri­to­ry for Nu­plazid, Aca­dia Phar­ma­ceu­ti­cals might have hit a dead end, with a Phase III fail­ure in schiz­o­phre­nia due to the place­bo arm per­form­ing bet­ter than ex­pect­ed.

“We will con­tin­ue to an­a­lyze these da­ta with our sci­en­tif­ic ad­vi­sors, but we do not in­tend to con­duct any fur­ther clin­i­cal tri­als with pi­ma­vanserin,” CEO Steve Davis said in a Mon­day press re­lease. Aca­dia’s stock $ACAD dropped by 17.41% be­fore the mar­ket opened Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.